Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash from Financing Activities (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Cash from Financing Activities for 8 consecutive years, with $86.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities changed N/A year-over-year to $86.9 million, compared with a TTM value of $92.7 million through Sep 2025, up 357.5%, and an annual FY2024 reading of $20.3 million, down 77.07% over the prior year.
  • Cash from Financing Activities was $86.9 million for Q3 2025 at X4 Pharmaceuticals, up from $5.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $86.9 million in Q3 2025 and bottomed at -$4.4 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $24.6 million, with a median of $12.9 million recorded in 2024.
  • The sharpest move saw Cash from Financing Activities crashed 1521.54% in 2021, then skyrocketed 20082.13% in 2023.
  • Year by year, Cash from Financing Activities stood at $24.6 million in 2021, then surged by 146.82% to $60.6 million in 2022, then plummeted by 99.84% to $97000.0 in 2023, then skyrocketed by 39.18% to $135000.0 in 2024, then skyrocketed by 64274.07% to $86.9 million in 2025.
  • Business Quant data shows Cash from Financing Activities for XFOR at $86.9 million in Q3 2025, $5.6 million in Q2 2025, and $135000.0 in Q4 2024.